We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apple
AAPL
$4.97T
| $4.39B | 6.8% |
16,161,971
-207,205
| -1% | -$55.6M |
|
|
2
Microsoft
MSFT
$2.9T
| $4.14B | 6.41% |
8,560,474
-125,427
| -1% | -$62.9M |
|
3
NVIDIA
NVDA
$4.6T
| $3.69B | 5.72% |
19,803,835
-259,181
| -1% | -$48.2M |
|
4
Amazon
AMZN
$2.44T
| $2.55B | 3.95% |
11,039,436
-153,300
| -1% | -$35.1M |
|
5
Alphabet (Google) Class A
GOOGL
$4.12T
| $2.52B | 3.9% |
8,049,743
-136,024
| -2% | -$38.9M |
|
|
6
Alphabet (Google) Class C
GOOG
$4.11T
| $2.08B | 3.22% |
6,628,189
-51,793
| -0.8% | -$14.8M |
|
7
Tesla
TSLA
$1.18T
| $1.87B | 2.9% |
4,168,252
-49,465
| -1% | -$21.9M |
|
8
Broadcom
AVGO
$1.76T
| $1.47B | 2.28% |
4,250,826
-32,497
| -0.8% | -$11.6M |
|
9
Meta Platforms (Facebook)
META
$1.49T
| $1.13B | 1.75% |
1,713,856
-44,158
| -3% | -$29.5M |
|
|
10
Eli Lilly
LLY
$1.08T
| $803M | 1.24% |
747,227
-97,776
| -12% | -$93.5M |
|
11
JPMorgan Chase
JPM
$916B
| $745M | 1.15% |
2,312,440
+4,665
| +0.2% | +$1.44M |
|
12
Visa
V
$701B
| $556M | 0.86% |
1,585,905
-27,986
| -2% | -$9.53M |
|
13
Johnson & Johnson
JNJ
$640B
| $525M | 0.81% |
2,538,487
+47,996
| +2% | +$9.49M |
|
14
AbbVie
ABBV
$465B
| $516M | 0.8% |
2,259,641
+4,225
| +0.2% | +$962K |
|
15
Mastercard
MA
$498B
| $515M | 0.8% |
902,444
-19,229
| -2% | -$10.7M |
|
16
Merck
MRK
$322B
| $490M | 0.76% |
4,651,002
+171,379
| +4% | +$16.1M |
|
17
Cisco
CSCO
$443B
| $468M | 0.72% |
6,070,293
-7,155
| -0.1% | -$531K |
|
18
Walmart Inc
WMT
$909B
| $412M | 0.64% |
3,698,376
-35,825
| -1% | -$3.85M |
|
19
Procter & Gamble
PG
$340B
| $384M | 0.6% |
2,682,786
-77,795
| -3% | -$11.5M |
|
20
GE Aerospace
GE
$364B
| $359M | 0.56% |
1,165,465
-25,785
| -2% | -$7.76M |
|
21
Coca-Cola
KO
$383B
| $340M | 0.53% |
4,861,421
+43,346
| +0.9% | +$3.02M |
|
22
IBM
IBM
$213B
| $336M | 0.52% |
1,133,448
-8,907
| -0.8% | -$2.67M |
|
23
Advanced Micro Devices
AMD
$700B
| $324M | 0.5% |
1,511,165
+4,388
| +0.3% | +$986K |
|
24
Bank of America
BAC
$429B
| $323M | 0.5% |
5,875,352
+86,626
| +1% | +$4.58M |
|
25
Welltower
WELL
$173B
| $319M | 0.49% |
1,720,000
-4,132
| -0.2% | -$772K |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.